OPKO Health Inc
OPK1.237USD
+0.047+3.98%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
964.90MCap. mercado
PérdidaP/E TTM
Más Datos de OPKO Health Inc Compañía
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older.
Información de la empresa
Símbolo de cotizaciónOPK
Nombre de la empresaOPKO Health Inc
Fecha de salida a bolsaNov 02, 1995
Director ejecutivoDr. Tony F. Cruz, Ph.D.
Número de empleados2997
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 02
Dirección- -
Ciudad- -
Bolsa de valoresNASDAQ Global Select Consolidated
País- -
Código postal- -
Teléfono- -
Sitio Web- -
Símbolo de cotizaciónOPK
Fecha de salida a bolsaNov 02, 1995
Director ejecutivoDr. Tony F. Cruz, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Dr. Tony F. Cruz, Ph.D.
Dr. Tony F. Cruz, Ph.D.
Chief Executive Officer, Transition Therapeutics, Inc
Chief Executive Officer, Transition Therapeutics, Inc
--
--
Dr. Roger J. Medel, M.D.
Dr. Roger J. Medel, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
116.21M
77.50%
Chile
14.53M
9.69%
Spain
6.44M
4.29%
Mexico
6.23M
4.15%
Ireland
5.48M
3.65%
Other
1.06M
0.71%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Frost Gamma Investments Trust
27.69%
Rubric Capital Management LP
6.02%
Holbrook (Bruce C)
5.09%
Hsiao (Jane H)
4.17%
Frost Group, L.L.C.
3.80%
Other
53.23%
Accionistas
Accionistas
Proporción
Frost Gamma Investments Trust
27.69%
Rubric Capital Management LP
6.02%
Holbrook (Bruce C)
5.09%
Hsiao (Jane H)
4.17%
Frost Group, L.L.C.
3.80%
Other
53.23%
Tipos de accionistas
Accionistas
Proporción
Corporation
36.58%
Hedge Fund
12.09%
Investment Advisor
10.34%
Individual Investor
10.23%
Investment Advisor/Hedge Fund
6.18%
Research Firm
1.84%
Bank and Trust
0.16%
Sovereign Wealth Fund
0.14%
Pension Fund
0.12%
Other
22.32%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
470
616.50M
77.74%
-1.20M
2025Q1
498
645.32M
88.41%
+25.74M
2024Q4
501
573.04M
84.80%
-7.63M
2024Q3
497
562.18M
81.01%
-12.00M
2024Q2
501
553.77M
79.70%
+8.59M
2024Q1
492
531.83M
76.52%
-21.84M
2023Q4
493
533.01M
69.65%
+31.42M
2023Q3
496
529.79M
69.24%
+23.70M
2023Q2
502
536.53M
70.13%
+25.42M
2023Q1
520
541.69M
71.63%
+67.95M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Frost Gamma Investments Trust
219.80M
27.72%
-26.90M
-10.90%
Apr 10, 2025
Rubric Capital Management LP
48.71M
6.14%
--
--
Mar 31, 2025
Holbrook (Bruce C)
40.38M
5.09%
--
--
Feb 24, 2025
Hsiao (Jane H)
33.13M
4.18%
--
--
Apr 02, 2025
Frost Group, L.L.C.
30.13M
3.8%
--
--
Apr 02, 2025
The Vanguard Group, Inc.
29.42M
3.71%
+293.74K
+1.01%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
24.77M
3.12%
-514.39K
-2.03%
Mar 31, 2025
GJN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
EGN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
Sculptor Capital Management, Inc
12.72M
1.6%
+12.72M
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
SPDR S&P Health Care Services ETF
0.69%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Amplify Weight Loss Drug & Treatment ETF
0.22%
VanEck Israel ETF
0.14%
iShares U.S. Healthcare Providers ETF
0.09%
Humankind US Stock ETF
0.09%
Vanguard US Momentum Factor ETF
0.08%
Invesco RAFI US 1500 Small-Mid ETF
0.05%
iShares Biotechnology ETF
0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.05%
Ver más
SPDR S&P Health Care Services ETF
Proporción0.69%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.44%
Amplify Weight Loss Drug & Treatment ETF
Proporción0.22%
VanEck Israel ETF
Proporción0.14%
iShares U.S. Healthcare Providers ETF
Proporción0.09%
Humankind US Stock ETF
Proporción0.09%
Vanguard US Momentum Factor ETF
Proporción0.08%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.05%
iShares Biotechnology ETF
Proporción0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporción0.05%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
